ArticleMolecular medicine (Cambridge, Mass.)2026
Colchicine attenuates kidney injury by modulating the NLRP3 inflammasome pathway.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColchicine, a well-known anti-inflammatory drug, has emerged as a therapeutic option in various inflammatory diseases. However, its role in chronic kidney disease (CKD) remains unclear. This study aims to investigate the reno-protective effects of colchicine in an experimental CKD model and its potential role in modulating the NOD-like receptor, pyrin domain containing protein 3 (NLRP3) inflammasome pathway.
methodsA CKD animal model was established in C57BL/6 mice by feeding a 0.2% adenine-containing diet. Colchicine (0.3 mg/kg/day) or saline was administered intraperitoneally for 4 weeks. RNA sequencing of kidney tissue was performed to capture molecular signatures associated with the therapeutic mechanism of colchicine in CKD. In vitro, renal tubular epithelial cells (RTECs) were treated with transforming growth factor-β (TGF-β, 10 ng/ml) and bone marrow-derived macrophages (BMDMs) were exposed to p-cresol sulfate (PCS, 0.5 mM). Colchicine (0.1 μM for RTECs and 1.0 μM for BMDMs) was administered to evaluate its protective effects.
resultsColchicine treatment significantly reduced systemic inflammatory markers including tumor necrosis factor-α, interleukin-6, and interleukin-1β. In the kidney tissues of adenine-fed mice, prominent fibrotic change and macrophage infiltration were observed, both of which were significantly attenuated by colchicine treatment. These improvements were accompanied by reduced albuminuria and improved kidney function. RNA sequencing revealed that colchicine modulated key inflammatory pathways, including the nuclear factor-κB and NOD-like receptor signaling pathway. Notably, colchicine treatment significantly decreased the expression levels of NLRP3 inflammasome components in adenine-fed mice, TGF-β-treated RTECs and PCS-treated BMDMs. Mechanistically, colchicine inhibited the interaction between NLRP3 and apoptosis-associated speck-like protein containing a CARD in TGF-β-treated RTECs and PCS-treated BMDMs, resulting in decreased NLRP3 inflammasome assembly, as demonstrated by oligomerization cross-linking assay and proximity-ligation assay.
conclusionsWe demonstrated that colchicine can attenuate kidney injury and fibrosis in adenine-induced CKD mice by inhibiting NLRP3 inflammasome assembly and activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.